α₁-Adrenergic receptors contribute to the acute effects of 3,4-methylenedioxymethamphetamine in humans
This study assessed the effects of the α₁-noradrenergic receptor antagonist, doxazosin (8mg/day for 3 days), on the acute response to MDMA (125mg) in healthy subjects (n=16). Doxazosin reduced MDMA-induced elevations in blood pressure, and body temperature, and moderately attenuated positive mood but enhanced tachycardia associated with MDMA.
Authors
- Matthias Liechti
- Cédric Hysek
Published
Abstract
Preclinical studies implicate a role for α₁-noradrenergic receptors in the effects of psychostimulants, including 3,4-methylenedioxymethamphetamine (MDMA, ecstasy). The present study evaluated the effects of the α₁-noradrenergic receptor antagonist doxazosin on the acute pharmacodynamic and pharmacokinetic response to MDMA in 16 healthy subjects. Doxazosin (8 mg/d) or placebo was administered for 3 days before MDMA (125 mg) or placebo using a randomized, double-blind, placebo-controlled, 4-session, crossover design. Doxazosin reduced MDMA-induced elevations in blood pressure, body temperature, and moderately attenuated positive mood but enhanced tachycardia associated with MDMA. The results indicate that α₁-adrenergic receptors contribute to the acute cardiostimulant and to a minor extent possibly also to the thermogenic and euphoric effects of MDMA in humans.
Research Summary of 'α₁-Adrenergic receptors contribute to the acute effects of 3,4-methylenedioxymethamphetamine in humans'
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Study Details
- Study Typeindividual
- Journal
- Compound
- Topics
- Authors
- APA Citation
Hysek, C. M., Fink, A. E., Simmler, L. D., Donzelli, M., Grouzmann, E., & Liechti, M. E. (2013). α₁-Adrenergic receptors contribute to the acute effects of 3,4-methylenedioxymethamphetamine in humans. Journal of Clinical Psychopharmacology, 33(5), 658-666. https://doi.org/10.1097/jcp.0b013e3182979d32
References (6)
Papers cited by this study that are also in Blossom
Liechti, M. E., Baumann, C., Gamma, A. et al. · Neuropsychopharmacology (2000)
Simmler, L. D., Hysek, C. M., Liechti, M. E. · Journal of Clinical Endocrinology Metabolism (2011)
Studerus, E., Gamma, A., Vollenweider, F. X. · PLOS ONE (2010)
Liechti, M. E., Gamma, A., Vollenweider, F. X. · Psychopharmacology (2001)
Hasler, F., Ludewig, S. · Journal of Psychopharmacology (2008)
Van Wel, J. H. P., Kuypers, K. P. C., Theunissen, E. L. et al. · PLOS ONE (2012)
Cited By (8)
Papers in Blossom that reference this study
La Torre, J. T., Mahammadli, M., Faber, S. et al. · International Journal of Mental Health and Addiction (2023)
Sarmanlu, M., Kuypers, K. P. C., Vizeli, P. et al. · Progress in Neuro-Psychopharmacology and Biological Psychiatry (2023)
Vizeli, P., Straumann, I., Duthaler, U. et al. · Frontiers in Pharmacology (2022)
Sarparast, A., Thomas, K., Malcolm, B. et al. · Psychopharmacology (2022)
La Torre, J. T., Mahammadli, M., Greenway, K. T. et al. · BMC Psychiatry (2022)
Regan, A., Margolis, S., De Wit, H. et al. · PLOS ONE (2021)
Bird, C. I. V., Modlin, N. L., Rucker, J. · International Review of Psychiatry (2021)
Papaseit, E., Torrens, M., Pérez-Mañá, C. et al. · Expert Opinion on Drug Metabolism and Toxicology (2018)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.